Milk fat globule-epidermal growth factor factor 8 (MFG-E8) is secreted from macrophages and is known to induce immunological tolerance mediated by regulatory T cells. However, the roles of the MFG-E8 that is expressed by cancer cells
| INTRODUCTION
In recent years, the human immune system has been recognized as having important roles in tumor progression. 1, 2 Because immune escape, which is caused by various factors such as regulatory cells, molecules, and cytokines, is associated with tumor development, the inhibition of these factors has been considered a promising treatment for cancer. [3] [4] [5] This strategy has proven effective with the successful development of antibody therapies blocking immune checkpoints, including anti-cytotoxic T-lymphocyte associated protein-4 or programmed cell death-1 (PD-1) therapy. 4 Therefore, it might be worth investigating other factors involved in immune suppression that are related to tumor progression.
Milk fat globule-epidermal growth factor factor 8 (MFG-E8), also known as lactadherin in humans, was originally identified as a glycoprotein that exists on the membrane of milk fat globule in the mammary duct 6, 7 and is known to be associated with adhesion to integrin-expressing cells. 8 This molecule is also secreted from various types of cells, including mammary epithelial cells, macrophages, and immature dendritic cells, and mediates the efficient engulfment of apoptotic cells by binding to α V β 3 integrin on phagocytes. [9] [10] [11] Mice deficient in MFG-E8 have defects in the removal of apoptotic cells and tend to develop autoimmune disease. 12 These results suggest a critical role for MFG-E8 in phagocytosis and the suppression of the immune response against apoptotic cells.
Furthermore, MFG-E8 expression in the tumor microenvironment was suggested to regulate the function of granulocyte macrophage colony-stimulating factor and to suppress antitumor immune responses through regulatory T cell (Treg) propagation. 13 When an anti-MFG-E8 blocking antibody was administered accompanied with the treatments that induce tumor cell apoptosis in mouse tumors, systemic and potent antitumor effects were observed with efficient dendritic cell cross-presentation, which leads to the activation of cytotoxic CD8 + T cells through the suppression of Treg induction. 14 Milk fat globule-epidermal growth factor factor 8 is reported to be expressed in several types of human cancer cells, as well as immune-related cells. Such expression has been found to be associated with tumor proliferation, epithelial-mesenchymal transition, cell migration, M2 macrophage polarization, and the induction of Tregs. [15] [16] [17] [18] [19] However, there are limited reports that clarified its prognostic impact on cancer patients. 16, 20 Table 1 ). The precise regimen is described elsewhere. 21 In the study period, the NAC was given to patients with tumors in any T category (cT1-4) accompanied with metastasis only to the regional or non-regional lymph nodes. The NAC was also given to patients with tumors classified as cT2 or more in depth with or without lymph node metastasis. The patients with metastatic lesions in distant organs other than the lymph nodes at the preoperative evaluation were excluded from the study. 22, 23 The characteristics of patients with and without NAC are described in Table 2 . Surgical treatment was carried out 3-8 weeks after 2 courses of NAC. The surgical procedure has been described previously. 24 The median follow-up period after the operation was 89.3 months. or with stable disease (with residual tumor and neither categorized as partial response nor PD) were defined as non-responders. 25 The pathological response was categorized into 5 groups according to the criteria of the Japanese Society for Esophageal Diseases. 26 The grades were as follows: grade 0, no therapeutic effect; grade1a, were defined as non-responders.
| Immunohistochemistry
Surgical samples were fixed in 10% phosphate-buffered formalin and embedded in paraffin. These formalin-fixed paraffin-embedded (FFPE) tissues were sliced into 3.5-μm-thick sections. Our immunohistochemistry (IHC) method is described elsewhere. 27 Briefly, the FFPE sections were deparaffinized in xylene and rehydrated in a 
| Statistical analyses
The associations between MFG-E8 expression and clinicopathological factors were analyzed by the χ 2 test. Relapse-free survival (RFS) and overall survival (OS) were calculated using the Kaplan-Meier method, and the log-rank test was used to assess the association between the survival and MFG-E8 expression or CD8/Foxp3 ratios.
A subgroup analysis of RFS and OS according to NAC history was undertaken using the same method. Hazard ratios and 95% confidence intervals of the variables were calculated using the Cox proportional hazard regression model. A multivariate Cox regression analysis was undertaken for the potential variables that could influence the survival. The difference of the CD8/Foxp3 ratios between high and low MFG-E8 expression groups was compared by the Wilcoxon rank sum test. Receiver operating characteristic (ROC) curve analysis was applied to determine the cut-off value for decreased CD8/Foxp3 ratio that affects the survival by using the 3-year OS as the end-point. 29 A two-sided P value less than 0.05 was considered 
| RESULTS

| Relationship between MFG-E8 expression and clinicopathological factors
Among the 134 patients, high MFG-E8 expression levels in the tumors were observed in 32 patients (23.9%). The relationships between MFG-E8 expression and clinicopathological factors are shown in Table 1 . In the group with high MFG-E8 expression, the frequency of patients with tumors located in the upper thoracic esophagus (P = .028), tumors with pathologically diagnosed advanced lymph nodes metastasis (pN2-3) (P = 0.015), or non-regional lymph node metastasis (pM1) (P = .0005) and a history of NAC (P < .0001)
were significantly higher compared with the patients with low MFG-E8 expression. There was no significant relationship between the intensity of MFG-E8 and other pathological factors such as sex, poorly differentiated tumor, tumor depth (pT), or tumor stage (pStage).
| Relationship between MFG-E8 expression and patient survival
Among all 134 patients, the RFS and OS of the high MFG-E8 expression group were significantly worse than those of the lowexpression group (P = .012 in RFS and P = .0047 in OS; Figure 2A ).
To minimize the differences in patient backgrounds (Table 2) , further analysis was undertaken in the subgroups divided according to the NAC history. Within the patients without NAC, there was no significant difference in the RFS or OS between those with high MFG-E8 expression and those with low expression (RFS, P = .65; OS, P = .68; Figure 2B ]. However, among patients treated with NAC, those with high MFG-E8 expression showed significantly shorter RFS and OS compared with those with low expression (RFS, P = .027; OS, P = .0039; Figure 2C ).
As shown in Table 3 , the high MFG-E8 expression group among patients who received NAC had a significantly larger percentage of N2-3 lymph node metastasis and non-regional lymph node metastasis. This observation was not made for the group without NAC (Table S1 ).
To analyze the causes that led to the worse survival rate of patients with high MFG-E8 expression after receiving NAC, the relationships between MFG-E8 expression and both the clinical and pathological response to therapy were examined. There were no relationships between these factors (Table 3 ).
| Relationship between expression of MFG-E8
and CD8 + T cell/Treg (Foxp3 + T cell) ratio 
| Relationship between CD8 + T cell/Treg ratio and survival in patients with NAC
To assess the influence of immunological status on tumor progression, the relationship between the CD8 + T cell/Treg (Foxp3 + T cell) ratio and the survival of patients with NAC was evaluated. The patients were divided into 2 groups according to the cut-off value determined with ROC curve analysis. The cut-off value was 3.2 with an area under the curve of 0.61. Twenty-eight patients had a CD8/ Foxp3 ≥ 3.2 (high CD8/Foxp3 group), and 38 patients had a CD8/ Foxp3 < 3.2 (low CD8/Foxp3 group). When the OS was compared between the two groups, the low CD8/Foxp3 group showed a significantly worse prognosis (P = .026; Figure 3C ). This finding might suggest that CD8 + T-cell suppression with Treg propagation leads to worse OS of patients treated with NAC.
| Univariate and multivariate analyses for factors associated with OS in patients treated with NAC
In the univariate analysis among patients with NAC history, poor tumor differentiation, pathologically diagnosed N2-3 lymph node metastasis, non-regional lymph node metastasis, tumor stage III-IV, and high MFG-E8 expression were the factors correlated with worse OS (Table 4 ). In the multivariate analysis, poor tumor differentiation, tumor stage III-IV, and high MFG-E8 expression were found to be independent prognostic factors (Table 4) .
| DISCUSSION
We examined MFG-E8 expression in human esophageal squamous cell carcinoma using IHC staining and found that some of the cells abundantly express MFG-E8, as shown in other types of cancer. [15] [16] [17] [18] [19] [20] 28, 30, 31 As the IHC staining of the samples showed that the expression of MFG-E8 was more abundant in cancer cells than in macrophages or other stromal cells, MFG-E8 from cancer cells appears to play an important role in the tumor microenvironment. Analysis of all patients examined showed that tumors with high MFG-E8 expression had a significantly higher possibility of having advanced lymph node and non-regional lymph node metastasis (M1), as previously suggested in malignant melanoma patients. 16 Our study also showed that the RFS and OS of the high MFG-E8 expression group were significantly worse than those of the low-expression group. These findings are consistent with the previous reports. 16, 20, 31 In the subgroup analysis according to the history of NAC showed unexpected characteristics associated with MFG-E8 expression of the tumors. In the patient group with NAC history, high MFG-E8 expression in the tumors correlated with worse RFS and OS. In both univariate and multivariate analyses, high MFG-E8 expression was found to be a statistically significant negative prognostic factor.
Because the unfavorable influence of abundant MFG-E8 expression on survival was only observed in patients who received NAC, we initially speculated that the effect might be associated with tumor resistance for the chemotherapy. However, our data showed no significant relationship between the MFG-E8 expression and the examined the relationship between MFG-E8 and tumor-associated macrophages by IHC on our surgical samples using methods similar to the previous study from our group 23 which examined the expression of total macrophages (M1 and M2) and independent M2 in esophageal cancer by CD68 and CD163 IHC staining, respectively. As a result, MFG-E8 expression in esophageal cancer had no relationship with total macrophages ( Figure S1 ) or M2 macrophages ( Figure S2 ).
The finding shown in prostate cancer was not seen in the surgical samples of esophageal cancer.
In the current study, there was a significantly higher rate of high The prognosis of esophageal cancer patients improved after NAC was introduced; 40, 41 however, even when treated with NAC, the 5-year survival rate remains as low as 59.2% among those who showed a good response to therapy. 42 Our results suggested that immunosuppression, which is possibly occurring after chemotherapy, might influence the long-term postoperative outcomes of patients.
Our previous study also showed that strong PD-L1 expression in esophageal squamous cancer cells after NAC was associated with reduced activity of CD8 + T cells and worse survival. 27 These results might suggest that various types of immunological escape occur in the tumor microenvironment, particularly after chemotherapy, and serve as critical events that strongly influence the outcome of the treatment. Therefore, the inhibition of the responsible molecules, including MFG-E8, could be a useful strategy to significantly improve the survival of esophageal cancer patients treated with chemotherapy.
In conclusion, abundant MFG-E8 expression in esophageal squamous cell carcinomas might have a negative influence on the long- Pathological classification in UICC (7th edition). CI, confidence interval; HR, hazard ratio; MFG-E8, milk fat globule-epidermal growth factor factor 8.
term survival of patients after chemotherapy by affecting T-cell regulation in the tumor microenvironment.
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